ライフサイエンスコーパス: aspartate transaminase

1 age histologically and by elevation of serum aspartate transaminase.

2 ive hepatocyte damage and elevation of serum aspartate transaminase.

3 Serum aspartate transaminase (70% vs. 31%, P =.04) and alkalin

4 lated malate dehydrogenase activity, but not aspartate transaminase activity, in HFD-fed mice.

5 Median peak aspartate transaminase after transplantation was 925 (in

6 LD activity score, steatosis, triglycerides, aspartate transaminase, alanine transaminase, and stella

7 tinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total

8 significant increases in the serum levels of aspartate transaminase, alanine transaminase, blood urea

9 (P =.002), diabetes mellitus (P =.009), and aspartate transaminase/alanine transaminase (AST/ALT) ra

10 ase level greater than 30 U/L, and (3) serum aspartate transaminase/alanine transaminase level less t

11 After OLT, the mean peak aspartate transaminase and alanine transaminase concentr

12 There were decreases in aspartate transaminase and alanine transaminase in the a

13 lesterol, uric acid, and the hepatic enzymes aspartate transaminase and alanine transaminase were sig

14 al (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage

15 in BCAT1 activity, but also by reductions in aspartate transaminase and glutamate dehydrogenase activ

16 ng had significantly reduced levels of serum aspartate transaminase and tumor necrosis factor-alpha,

17 rved in serum aminotransferases (alanine and aspartate transaminases) and lactate dehydrogenase level

18 alkaline phosphatase, alanine transaminase, aspartate transaminase, and bile acids.

19 with other renal injury markers (creatinine, aspartate transaminase, and heart-type fatty acid bindin

20 lower peak serum alanine transaminase (ALT), aspartate transaminase, and higher peak serum alkaline p

21 acebo, levels of gamma-glutamyl transferase, aspartate transaminase, and soluble tumor necrosis facto

22 of apoptotic hepatocytes, serum alanine and aspartate transaminases, and DNA fragments in the cytoso

23 ignificant difference in peak serum alanine, aspartate transaminases, and lactate dehydrogenase after

24 040), aspartate transaminase (AST) (135.5 +/- 52.3 to 56.3 +/-

25 lirubin (0.9 +/- 0.1 vs. 1 +/- 0.1, P =.07), aspartate transaminase (AST) (58 +/- 5 vs. 56 +/- 6, P =

26 ambs, which were accompanied by elevation of aspartate transaminase (AST) (P <.01).

27 Concomitantly, serum aspartate transaminase (AST) activity was significantly

28 (-/-) mice manifested as profoundly elevated aspartate transaminase (AST) and alanine transaminase (A

29 ated by using a model enzyme pair comprising aspartate transaminase (AST) and malic dehydrogenase.

30 lammation (CLNI) associated with an elevated aspartate transaminase (AST) level and portal tract feat

31 vealed that recipient age, serum creatinine, aspartate transaminase (AST) level, presence of edema, d

32 chemia/reperfusion (IR) injury with 24 hours aspartate transaminase (AST) levels >2000 IU/L (Group A)

33 HCV infection associated with elevated serum aspartate transaminase (AST) levels predicted the develo

34 n only a few weeks, and after 8 weeks, serum aspartate transaminase (AST) levels were doubled.

35 After 4 weeks, serum aspartate transaminase (AST) levels were elevated in eth

36 After reperfusion, serum aspartate transaminase (AST) levels were reduced up to 3

37 iglycerides, alanine transaminase (ALT), and aspartate transaminase (AST) were measured.

38 iption polymerase chain reaction) as well as aspartate transaminase (AST), alanine transaminase (ALT)

39 r greater were associated with elevated ALT, aspartate transaminase (AST), and gamma-glutamyl transpe

40 liver enzymes, alanine transaminase (ALT) or aspartate transaminase (AST), are commonly used in clini

41 une hepatitis (AIH) by lower serum levels of aspartate transaminase (AST), gamma-globulin, and immuno

42 change from baseline was found in mean ALT, aspartate transaminase (AST), GGT, bilirubin, triglyceri

43 After 4 weeks, serum aspartate transaminase (AST), necrosis and inflammation

44 Peak transaminase (aspartate transaminase [AST] and alanine transaminase [A

45 markers of hepatic parenchymal injury (e.g., aspartate transaminase [AST], lactate dehydrogenase [LDH

46 epatic enzymes (alanine transferase, ALT and aspartate transaminase, AST) were only significantly obs

47 elevations in alanine amino transferase and aspartate transaminase at this dose level indicate that

48 ]/mg of creatinine, plasma homocysteine, and aspartate transaminase by more than 8-fold.

49 nor age, steatosis, cold ischemic time, peak aspartate transaminase, day 5 bilirubin or international

50 eumonia (13/10), and alanine transaminase or aspartate transaminase elevations (60/20).

51 ere it can be converted into oxaloacetate by aspartate transaminase (GOT1).

52 Plasma levels of TNF-alpha and aspartate transaminase in double-infected mice were grea

53 (32%), alanine transaminase increase (20%), aspartate transaminase increase (15%), anemia and thromb

54 ount, urea, bilirubin, alanine transaminase, aspartate transaminase, international normalized ratio,

55 iated with a significantly higher mean serum aspartate transaminase level (P =.

56 Time to significant fibrosis (defined as an aspartate transaminase level to platelet count ratio ind

57 Endpoints included peak serum aspartate transaminase level, postoperative complication

58 on for 4 weeks significantly increased serum aspartate transaminase levels and hepatic pathology scor

59 Elevated serum aspartate transaminase levels confirmed that mortality w

60 Alanine transaminase and aspartate transaminase levels followed a sawtooth patter

61 Serum aspartate transaminase levels were elevated in ethanol-t

62 otoxicity (grade 3 or 4 change in alanine or aspartate transaminase levels) among 568 patients receiv

63 30.5), alanine aminotransferase levels, and aspartate transaminase levels.

64 ts, and had higher pre-ART triglycerides and aspartate transaminase levels.

65 t clamping (P = 0.015) significantly reduced aspartate transaminase levels.

66 the serum levels of alanine transaminase and aspartate transaminase (p<0.05).

67 s generated from unlabeled glutamate via the aspartate transaminase reaction.

68 297 +/- 56, PUGNAc: 126 +/- 21 IU, p < .05), aspartate transaminase (sham surgery: 536 +/- 110, contr

69 including either end-stage liver disease or aspartate transaminase to platelet ratio index (APRI) of

70 og creatinine, log alanine transaminase, log aspartate transaminase, UNOS status, donor gender, and w

71 Postoperative peak of aspartate transaminase was defined as primary endpoint,

72 Elevated alanine transaminase/aspartate transaminase was seen in 67% of patients (23%